INO-3107 Awarded The Innovation Passport Designation Under U.K. Government's Innovative Licensing And Access Pathway Granted By The ILAP Steering Group To INO-3107 For The Treatment Of Patients With Recurrent Respiratory Papillomatosis
INO-3107 Awarded The Innovation Passport Designation Under U.K. Government's Innovative Licensing And Access Pathway Granted By The ILAP Steering Group To INO-3107 For The Treatment Of Patients With Recurrent Respiratory Papillomatosis
Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP)
该奖项认可INO-3107有望成为英国治疗复发性呼吸道乳头状瘤（RRP）患者的第一治疗选择。
PLYMOUTH MEETING, Pa., July 11, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its lead DNA medicine candidate, INO-3107, has been designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP). The designation, called an Innovation Passport, was granted by the ILAP Steering Group to INO-3107 for the treatment of patients with Recurrent Respiratory Papillomatosis (RRP), a debilitating, chronic rare disease of the respiratory tract caused by HPV-6 and/or HPV-11.
宾夕法尼亚州普利茅斯会议，2024年7月11日/美通社/-- 纳斯达克（NASDAQ:INO）的生物技术公司INOVIO专注于开发和商业化DNA药物，以帮助治疗和预防人类乳头瘤病毒相关疾病、癌症和传染病，今天宣布，其主导的DNA药物候选者INO-3107已被英国创新许可和获取途径（ILAP）的创新医药指定为创新药物。这一称号，称为创新护照，由ILAP指导小组授予INO-3107，用于治疗由HPV-6和/或HPV-11引起的呼吸道复发性乳头状瘤（RRP）患者，这是一种慢性罕见的呼吸道疾病。